Finally some news. And no real surprises on the LTC front. No partner in sight....so I agree that the selling is a result of the ambiguity of the future of LTC....and Allison chipping away at his 100k a month.
In essence, the BOD has stated their intent to commercialize LTC on their own. Like it or not, the costs involved in rolling out a new technology like LTC are well beyond the company's current financial means. On what terms will Empire (or anyone) front CTGI what amounts to 10's of millions of dollars (rough guess) to start up the biz? Will the current board be as frugal with issuing new shares as DR was? Then again, a low O/S with no progress isn't a very happy outcome either.
Remember, there are huge costs in PR, production, and demonstrating LTC at conferences and in hospital. It's hard to believe that a huge med company wouldn't jump at the chance to control a chunk of LTC if the reports from the Ukraine are all true.
CCTI looks more promising. Hopefully it will play a role similar to LTC when the C02 separator was supposed to drive the company ahead financially and pave the way for FDA approval of LTC.
What a long, strange trip it's been!
